Mogamulizumab

Phase 2Active

1 views this week 0 watching💤 Quiet🧪Featured in Gene & Cell Therapy Watch

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous T-Cell Lymphoma, Relapsed

Conditions

Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory

Trial Timeline

Aug 16, 2021 → May 1, 2025

NCT ID

NCT04745234

About Mogamulizumab

Mogamulizumab is a phase 2 stage product being developed by Kyowa Kirin for Cutaneous T-Cell Lymphoma, Relapsed. The current trial status is active. This product is registered under clinical trial identifier NCT04745234. Target conditions include Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous T-Cell Lymphoma, Relapsed were approved

Approved (7) Terminated (1) Active (12)

✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved

✅ONTAKEisaiApproved

✅MogamulizumabKyowa KirinApproved

✅Clopidogrel + TicagrelorAstraZenecaApproved

✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved

✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06285370	Approved	Active	May 29, 2023	Nov 13, 2025	Cutaneous T-Cell Lymphoma
NCT04745234	Phase 2	Active	Aug 16, 2021	May 1, 2025	Cutaneous T-Cell Lymphoma, Relapsed

Competing Products

20 competing products in Cutaneous T-Cell Lymphoma, Relapsed

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	43
ONTAK	Eisai	Approved	43
E7777 9 mcg/kg	Eisai	Phase 3	40
ONTAK	Eisai	Approved	43
Mogamulizumab	Kyowa Kirin	Approved	47
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	36
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	40
Enzastaurin	Eli Lilly	Phase 2	35
Clopidogrel + Ticagrelor	AstraZeneca	Approved	43
Pembrolizumab	Merck	Phase 2	42
Comparator: vorinostat	Merck	Pre-clinical	26
Pembrolizumab	Merck	Phase 2	39
TR701 FA	Merck	Phase 2	35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Tulisokibart + Placebo	Merck	Phase 2	39
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	35
Pembrolizumab + Mogamulizumab	Merck	Phase 2	42
TR-701 FA + Linezolid	Merck	Phase 3	40
Pimasertib + Dacarbazine	Merck	Phase 2	35